Dr. Rule on the Combination of Venetoclax and Ibrutinib in MCL

Video

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in mantle cell lymphoma (MCL).

Only 1 study has been published on the combination of venetoclax and ibrutinib in MCL. Although the study was small, it showed a high complete remission (CR) rate of 63% in a heavily pretreated group of patients, says Rule. Moreover, investigators noted a high rate of minimal residual disease negativity which has enabled some patients to stop therapy.

These are very encouraging data. Now, a phase III trial is planned to evaluate the venetoclax/ibrutinib combination versus ibrutinib alone in the relapsed/refractory setting. Additionally, Rule is currently leading a trial that is looking at the combination of ibrutinib and rituximab (Rituxan) in the frontline setting in elderly patients with the disease. Chemotherapy will serve as the comparator arm of that trial, says Rule. These data will shed light on whether a chemotherapy-free regimen is superior to chemotherapy in the frontline setting. Even if the data do not indicate that the combination is better than chemotherapy, it illustrates the push toward a chemotherapy-free paradigm.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,